Cytokinetics's Omecamtiv Mecarbil Shows No Effect On Exercise Capacity In Heart Failure Patients

Cytokinetics Incorporated CYTK announced the full results from the METEORIC-HF Phase 3 trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF).
METEORIC-HF evaluated the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity.
After 20 weeks of treatment, no effect of omecamtiv mecarbil on exercise capacity was observed versus placebo.
Also See: Cytokinetics Posts Cohort 3 Data From Aficamten Trial In Heart Disease Patients.
Patients treated with omecamtiv mecarbil had an average change from baseline in pVO2 of -0.2 ml/kg/min compared to 0.2 ml/kg/min for patients on placebo.
No beneficial effect was observed in any of the secondary endpoints, including change in total workload during exercise, change in ventilatory efficiency, and change in daily physical activity.
Additional data from GALACTIC-HF were also presented, including a healthcare resource utilization analysis and the effect of omecamtiv mecarbil in hospitalized patients compared to outpatients.
In the selected subgroup of the GALACTIC-HF trial, omecamtiv mecarbil was associated with significant reductions in risk of a first heart failure event (relative risk reduction (RRR) 15%, absolute risk reduction (ARR) 3.8, number needed to treat (NNT) 26.2), total HF events (RRR 17%, ARR 6.8, NNT 14.7), and cumulative heart failure events.
The rate of the primary outcome was higher in hospitalized patients in the placebo group (38.3/100 person-years [PY]) than in outpatients (23.1/100 PY) with an adjusted hazard ratio (HR) of 1.21.
Price Action: Friday, CYTK shares closed 4.27% higher at $38.38.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga